Sagun Parakh
Sagun Parakh
Unknown affiliation
Verified email at monash.edu
Title
Cited by
Cited by
Year
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, ...
British journal of cancer 114 (10), 1084-1089, 2016
1012016
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
S Parakh, JJ Park, S Mendis, R Rai, W Xu, S Lo, M Drummond, C Rowe, ...
British journal of cancer 116 (12), 1558-1563, 2017
862017
Evolution of anti-HER2 therapies for cancer treatment
S Parakh, HK Gan, AC Parslow, IJG Burvenich, AW Burgess, AM Scott
Cancer treatment reviews 59, 1-21, 2017
732017
Antibody–drug conjugates for cancer therapy
AC Parslow, S Parakh, FT Lee, HK Gan, AM Scott
Biomedicines 4 (3), 14, 2016
702016
Autoantibodies may predict immune-related toxicity: results from a Phase I study of intralesional Bacillus Calmette–Guérin followed by ipilimumab in patients with advanced …
J Da Gama Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, ...
Frontiers in immunology 9, 411, 2018
322018
Late presentation of generalised bullous pemphigoid‐like reaction in a patient treated with pembrolizumab for metastatic melanoma
S Parakh, R Nguyen, JM Opie, MC Andrews
Australasian Journal of Dermatology 58 (3), e109-e112, 2017
292017
Antibody-mediated delivery of therapeutics for cancer therapy
S Parakh, AC Parslow, HK Gan, AM Scott
Expert opinion on drug delivery 13 (3), 401-419, 2016
282016
Outcomes of haematology/oncology patients admitted to intensive care unit at T he C anberra H ospital
S Parakh, A Piggin, T Neeman, I Mitchell, P Crispin, A Davis
Internal medicine journal 44 (11), 1087-1094, 2014
262014
Antibody–Drug Conjugates for Cancer Therapy
U Hafeez, S Parakh, HK Gan, AM Scott
Molecules 25 (20), 4764, 2020
242020
Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti‐PD‐1 Therapy
S Parakh, J Cebon, O Klein
The oncologist 23 (7), 849, 2018
242018
Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a
IJG Burvenich, S Parakh, HK Gan, FT Lee, N Guo, A Rigopoulos, ST Lee, ...
Journal of Nuclear Medicine 57 (6), 974-980, 2016
192016
Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia
S Parakh, HL Wong, R Rai, S Ali, K Field, J Shapiro, R Wong, L Nott, ...
Journal of geriatric oncology 6 (5), 387-394, 2015
182015
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a
IJG Burvenich, S Parakh, FT Lee, N Guo, Z Liu, HK Gan, A Rigopoulos, ...
Theranostics 8 (15), 4199, 2018
172018
Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
S Parakh, C Murphy, D Lau, JS Cebon, MC Andrews
Journal of clinical pharmacy and therapeutics 40 (1), 121-123, 2014
162014
Receptor occupancy imaging studies in oncology drug development
IJG Burvenich, S Parakh, AC Parslow, ST Lee, HK Gan, AM Scott
The AAPS journal 20 (2), 1-16, 2018
132018
Regorafenib-induced hyperammonemic encephalopathy.
JC Kuo, S Parakh, D Yip
Journal of clinical pharmacy and therapeutics 39 (4), 446-448, 2014
112014
Current development of monoclonal antibodies in cancer therapy
S Parakh, D King, HK Gan, AM Scott
Current Immunotherapeutic Strategies in Cancer, 1-70, 2020
92020
Real‐world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma
S Parakh, M Randhawa, B Nguyen, L Warburton, MA Hussain, J Cebon, ...
Asia‐pacific Journal of Clinical Oncology 15 (1), 26-30, 2019
92019
Novel approaches to undergraduate oncology education
FJ Ha, S Parakh
Journal of Cancer Education 33 (3), 500-504, 2018
92018
Cholecystitis after yttrium-90 resin microsphere radioembolization treatment: clinical and pathologic findings
S Parakh, S Gananadha, R Allen, D Yip
Asian journal of surgery 39 (3), 144-148, 2016
92016
The system can't perform the operation now. Try again later.
Articles 1–20